Table 2 Relationship between treatment,... | American Society of Hematology

Table 2

Relationship between treatment, stage, age and sex, and PFS and OS in the patients genotyped

	N	OS			PFS
	N	No. deaths	O/E ratio	P*	Progression or death	O/E ratio	P*
Treatment
Chlorambucil	206	48	0.87	.3	155	1.36	< .001
Fludarabine	112	33	1.16	—	75	1.12	—
Fludarabine and cyclophosphamide	107	33	1.08	—	52	0.51	—
Stage
A	104	20	0.67	< .001	66	0.94	.03
B	186	45	0.88	—	116	0.87	—
C	135	49	1.5	—	100	1.28	—
Age
Less than 60 y	127	21	0.51	< .001	88	1.01	.8
60 to 69 y	168	42	0.94	—	109	0.96	—
Over 70 y	130	51	1.81	—	85	1.05	—
Sex
Male	312	88	1.05	.4	218	1.08	.02
Female	113	26	0.87	—	64	0.79	—

	N	OS			PFS
	N	No. deaths	O/E ratio	P*	Progression or death	O/E ratio	P*
Treatment
Chlorambucil	206	48	0.87	.3	155	1.36	< .001
Fludarabine	112	33	1.16	—	75	1.12	—
Fludarabine and cyclophosphamide	107	33	1.08	—	52	0.51	—
Stage
A	104	20	0.67	< .001	66	0.94	.03
B	186	45	0.88	—	116	0.87	—
C	135	49	1.5	—	100	1.28	—
Age
Less than 60 y	127	21	0.51	< .001	88	1.01	.8
60 to 69 y	168	42	0.94	—	109	0.96	—
Over 70 y	130	51	1.81	—	85	1.05	—
Sex
Male	312	88	1.05	.4	218	1.08	.02
Female	113	26	0.87	—	64	0.79	—

O/E ratio indicates observed versus expected ratio.

Log-rank test for trend.